MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)
Previous Close
$46.76
52W Range
$35.53 - $64.98
50D Avg
$49.17
200D Avg
$47.31
Market Cap
$2.92B
Avg Vol (3M)
$309.05K
Beta
1.26
Div Yield
-
MLTX Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Performance
Peer Comparison
Ticker | Company |
---|---|
PLRX | Pliant Therapeutics, Inc. |
NUVL | Nuvalent, Inc. |
AKRO | Akero Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
VTYX | Ventyx Biosciences, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
CERE | Cerevel Therapeutics Holdings, Inc. |
TVTX | Travere Therapeutics, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
ACLX | Arcellx, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
GPCR | Structure Therapeutics Inc. |
ETNB | 89bio, Inc. |
ELVN | Enliven Therapeutics, Inc. |
CMPX | Compass Therapeutics, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |